v3.26.1
Segment
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
Segment Segment
The chief operating decision maker for the Company is the Chief Executive Officer, who reviews financial information presented on a consolidated basis for purposes of allocating resources and assessing financial performance. The Company has a single reporting unit associated with the development and commercialization of diagnostic tests and biopharmaceutical services. The accounting policies of the Company's single segment are the same as those described in the summary of significant accounting policies in Note 1, Organization, Description of Business and Summary of Significant Accounting Policies. The chief operating decision maker assesses performance of the Company's single segment and decides how to allocate resources based on consolidated net income. Under the current organizational structure, this measure is not discretely available or required individually for any of the Company’s business activities and is only available at the consolidated level. The monitoring of budgeted versus actual results are used in assessing performance of the Company's single segment, allocating resources and in establishing management’s compensation. The Company's chief operating decision maker intends for all revenue generating activities to rely on cross-functional activities across the consolidated entity in order to operate. No individual besides the chief operating decision maker has been tasked with reviewing discrete operating results of the business activities, nor is there any intent to bifurcate the overall business review process to produce discrete operating results specific to any of the Company's business activities. The measure of segment assets is reported on the consolidated balance sheet as total consolidated assets. Consolidated revenue does not include any inter-segment sales or transfers.
Information about reported segment revenue, measures of segment profit or loss, significant segment expenses and reconciliation to income from operations was as follows (in thousands):

Three Months Ended June 30,Six Months Ended June 30,
2026202520262025
Revenue:
Testing revenue$145,661 $122,263 $280,752 $229,572 
Product revenue3,858 3,598 7,537 7,178 
Biopharmaceutical and other revenue802 4,303 1,103 7,887 
Total revenue150,321 130,164 289,392 244,637 
Cost of revenue:
Cost of testing revenue:
Laboratory supplies and reagents expense13,846 15,304 26,161 28,369 
Sample collection expense3,644 3,494 6,932 6,320 
Compensation expense9,858 6,023 19,662 11,634 
Other cost of testing revenue (1)5,884 4,173 10,820 7,559 
Allocation of facilities and IT expenses3,077 3,413 6,040 6,785 
Total cost of testing revenue36,309 32,407 69,615 60,667 
Cost of product revenue:
Product costs1,985 705 3,386 813 
License fees and royalties336 307 649 631 
Other cost of product revenue (2)190 515 364 1,309 
Allocation of facilities and IT expenses4 222 7 418 
Total cost of product revenue2,515 1,749 4,406 3,171 
Cost of biopharmaceutical and other revenue:
Compensation expense— 1,652 — 2,892 
Other cost of biopharmaceutical and other revenue (3)207 1,462 215 2,506 
Allocation of facilities and IT expenses— 458 — 872 
Total cost of biopharmaceutical and other revenue207 3,572 215 6,270 
Intangible asset amortization - cost of revenue2,741 2,667 5,448 5,252 
Gross profit108,549 89,769 209,708 169,277 
Operating expenses:
Research and development:
Compensation expense16,820 9,063 32,367 18,812 
Direct research and development expense3,785 3,292 7,984 7,434 
Other research and development expenses (4)6,789 1,880 12,248 3,692 
Allocation of facilities and IT expenses2,048 2,029 3,941 4,046 
Total research and development29,442 16,264 56,540 33,984 
Selling and marketing:
Compensation expense19,574 17,601 39,545 35,236 
Direct marketing expense2,706 1,478 4,162 2,188 
Other selling and marketing expenses (5)4,559 3,696 9,120 7,549 
Allocation of facilities and IT expenses1,424 2,541 2,592 4,797 
Total selling and marketing28,263 25,316 55,419 49,770 
General and administrative:
Compensation expense18,446 21,260 34,683 41,433 
Other general and administrative expenses (6)15,550 19,734 29,020 41,624 
Allocation of facilities and IT expenses(6,553)(8,663)(12,580)(16,918)
Total general and administrative27,443 32,331 51,123 66,139 
Impairment of assets— 20,505 — 20,505 
Intangible asset amortization - operating expenses421 621 1,000 1,243 
Other income, net(3,543)(6,518)(10,871)(11,042)
Income tax provision1,033 2,230 2,300 2,611 
Net income (loss)$25,490 $(980)$54,197 $6,067 
________________

(1)Other cost of testing revenue includes cytopathology services, depreciation and amortization and other expenses.
(2)Other cost of product revenue includes contract manufacturing fees, license fees and royalties, depreciation and amortization and other expenses.
(3)Other cost of biopharmaceutical and other revenue includes professional fees, information technology expense, depreciation and amortization and other expenses.
(4)Other research and development expenses include depreciation and amortization and other expenses.
(5)Other selling and marketing expenses include travel, entertainment, conference and other expenses.
(6)Other general and administrative expenses include professional fees, information technology expense, occupancy costs, depreciation and amortization, contingent consideration and other expenses.